Work

Abstract CT216: OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct216

Authors: J. Randolph Hecht, Elena Élez, Cathy Eng, Peter Gibbs, Jenny Seligmann, Ruihua Xu, Kensei Yamaguchi, Jaw Yuan Wang, Hao Wei Teng, Leonardo Trani, Honeylet Wortman-Vayn, Zhengyu Jiang, Brooke Diorio, Patricia Lorenzini, Christine Baudelet, Seema Sethi, Mahadi Baig, Chiara Cremolini

Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Vall d'Hebron Hospital Universitari, Vanderbilt-Ingram Cancer Center, Sunshine Hospital, St James's University Hospital, Sun Yat-sen University, Sun Yat-sen University Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Kaohsiung Medical University, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taipei Veterans General Hospital, Johnson & Johnson (United States), Azienda Ospedaliera Universitaria Pisana

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154682432

Cites:

Cited by: 1

Related to: